High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis [Abstract LB-15]

Publication Type:

Conference Paper

Source:

52nd Annual Meeting of the European Association for the Study of the Liver (EASL) (2017)
Top